Deal brings GammaCan a step closer to filing an IND application.

Bio Products Laboratory’s (BPL) will manufacture GammaCan’s cancer immunotherapy, VitiGam™. The candidate is being developed for Stage III and Stage IV melanoma. Currently, GammaCan is in pre-IND meetings with the FDA related to the IgG-based product.

BPL will manufacture the compound from plasma derived from donors suffering from vitiligo utilizing its Gammaplex process. The multiyear agreement covers clinical-trial and commercial-level supply of VitiGam.

In addition, the agreement provides that BPL will provide the company with technical, scientific, and other data including specific support for its U.S. regulatory filings and future regulatory approvals in other markets.

Previous articleGen-Probe Bids $332M for Innogenetics
Next articleJiangsu Aosaikang Pharmaceutical Negotiates Chinese Rights to Access Pharma’s Phase II Cancer Drug